SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: charles moore who wrote (7092)8/31/1998 7:57:00 PM
From: Dan O  Read Replies (1) | Respond to of 17367
 
Ellen Martin,

I know you check out the boards. What can you say about these concerns? Certainly, a buyout at a small premium to todays market would be an insult to most shareholders since most have probably bought in at double or triple today's level. Further, a buyout at low prices during a temporary slump in biotech stocks right before anticipated FDA action would surely result in well rewarded shareholder suits. Can the company provide the shareholders with comfort in this regard so we can put this aside? Perhaps you can share the intended use of the study and its preliminary results? I believe you have posted here before. It would be helpful to do so again.

Dan O



To: charles moore who wrote (7092)8/31/1998 9:08:00 PM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
I cant say what Mr Castello will do, but he didnt sell out the last time at $1.125.
Shareholders DO NOT want any buyout here. Not at 50% premium, not at 100%. Not at 150% . Not at all.
Pass it on Ellen.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News